Longevity takes the stage once again on the streets of Davos during this year's World Economic Forum (WEF).
In pursuit of answers on how we can prepare to age healthy and lead a long and fulfilling life, the "Longevity Investors Lunch", a satellite event dedicated to exploring longevity and rejuvenation, convened during the World Economic Forum on January 16th. This gathering brought together prominent scientists, academics, entrepreneurs, and investors to discuss the latest technologies and research in the field. Co-organized by Maximon and Longevity Investors, the event served as a prelude to the upcoming "Longevity Investors Conference" scheduled for September 24-27, 2024, at Le Grand Bellevue Hotel in Gstaad, Switzerland.
In a completely oversubscribed event, more than 60 investors and influential thought leaders convened, showcasing the remarkable progress achieved in the field of longevity. The event focused on the hallmarks of longevity, brain longevity, longevity supplements and the synergy between AI and longevity.
Biologist and author of Ageless, Dr. Andrew Steele gave a talk on “The hallmarks of longevity: a framework for science, investing and regulation”, where he revealed how understanding the scientific implications of ageing could lead to the greatest revolution in the history of medicine—one that has the potential to improve lives, save money, and transform the human condition.
The three panels, moderated by Sabinije von Gaffke (Head of Sustainability, Nibiru Software) and Hans Keirstead, Ph.D. (Chairman of the Board, Immunis) covered the following topics: unlocking the secrets of brain longevity, exploring the world of longevity supplements and also the latest developments in longevity and AI. The discussions on stage featured renowned experts and prominent longevity venture builders such as Evelyne Yehudit Bischof, MD, PhD, MPH (Director, Sheba Longevity Center), Alex Zhavoronkov, Ph.D. (Founder and CEO, Insilico Medicine), Rajiv Ahuja, JD (Associate Director, Milken Institute Future of Aging), Hans Keirstead, Ph.D. (Chairman of the Board, Immunis), Sophie Chabloz (Co-Founder and CPO, Avea), Dr. Emil Kendziorra (Founder and CEO at Tomorrow Biostasis) and Nika Pintar (Chief, AniBiome).
The hosts of the event, Dr. Tobias Reichmuth and Marc P. Bernegger (both Co-Founders of Maximon and Longevity Investors) opened the event while talking about the latest developments in the industry and closed it by explaining why company building in longevity is needed now.
“We are very proud to bring the important topic of longevity to Davos. We are already looking forward to the Longevity Investors Conference, where we will have the opportunity to continue the important conversations we started in Davos and involve more longevity leaders on stage”, says Marc P. Bernegger, Founding Partner at Maximon and the organizer of the Longevity Investors Conference in Gstaad.
The “Longevity Investors Conference” is the most exclusive conference for longevity investors. It gathers a selected audience of the most prominent investors in the field. The main aim of the event is to bring together academia and business to discuss the latest trends, and opportunities and to provide relevant insights into the longevity and rejuvenation subject.
The motivation to organize the “Longevity Investors Conference”, said Dr. Tobias Reichmuth, is clear: “The longevity industry is highly attractive for investors. We state a lack of education and information for investors and want to change this.”
Longevity has emerged as a formidable influencer in shaping the global economy, unlocking opportunities worth trillions of dollars and offering the potential to transform societies positively. In recent years, it has undergone a groundbreaking evolution, thanks in part to the revelation that genetic pathways and biochemical processes play a role in controlling the rate of aging. As we navigate the future, longevity is poised to become not only a significant but possibly the most substantial investment opportunity of the upcoming decades. While Maximon is self-financed, it has set up a Co-Investment Fund with a target volume of CHF 100 million.
In January 2024, Maximon launched an additional investment vehicle for the Co-Investment Fund targeting qualified investors. For further information, please reach out via [email protected].
For more information and details please visit www.longevityinvestors.ch.
Follow us on Linkedin
Follow us on Twitter
Follow us on Instagram